CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 236 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01328158
NCT01328158N/ACompleted

Drug Use Investigation of Kaletra Tablets (Quaque Die, QD) on Patients With HIV-infection

AbbVie (prior sponsor, Abbott)·observational·Posted Apr 4, 2011·Updated Dec 22, 2014

In Brief

An observational study for Human Immunodeficiency Virus Infection. Completed, enrolled 236 participants across 23 sites.

Detailed Summary

This study of Kaletra (Lopinavir (LPV)/Ritonavir (RTV)) tablets will be conducted to clarify the following with regard to treatment with this drug: 1. Incidence and conditions of occurrence of adverse reactions in the clinical setting 2. Factors that may affect the safety and effectiveness of Kaletra (QD)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 4, 2011
Enrollment StartJun 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 15.2 years ago